Effect of Re-esterified Triglyceride (rTG) Form Omega-3 Supplements on Dry Eye Following Cataract Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04411615

Enrollment

Registered

2020-06-02

Start date

2020-07-01

Completion date

2021-02-28

Last updated

2020-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye

Brief summary

To evaluate the clinical outcomes of the systemic re-esterified triglyceride (rTG) form of omega-3 fatty acids in patients with dry eye symptoms after cataract surgery

Interventions

DRUGOmega 3

rTG form Omega-3

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Non complicated cataract surgery * Patients with dry eye symptom

Exclusion criteria

* Using steroid eyedops, * Using antibiotics eyedrops * Surgery other than Cataract surgery * Contact lens wearer * Other systemic disease

Design outcomes

Primary

Measure	Time frame	Description
Dry eye symptom	1 month	Improvement of symptom

Contacts

Primary ContactTae-Young Chung

tychung@skku.edu82-2-3410-3563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026